Financials
Financial year 2025
ULTIMEDI from Wingene, company number BE0834340946, closed financial year 2025 with a result of € -141,203 after tax. For that financial year ULTIMEDI recorded revenue of € 11.3 million and equity of € 1.9 million. Compared with financial year 2024, the result moved from € 330,890 to € -141,203. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ 1.9 million
▼ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -141,203
▼ still € 330,890 profit in 2024
Profit after tax over the fiscal year.
€ 42,088
▼ 62% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 1.9 million.
People and assets in 2025
18.4
▲ 1.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.1 million
▲ 101% vs 2024
€ 57,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 58,636
▲ 203% vs 2024
Of which on lease € 36,755.
Debts at end 2025
€ 1.2 million
▲ 23% vs 2024
€ 81,602 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 2.1 million
▲ € 1.7 million vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 73 days on average.
€ 106,645
▼ 11% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 4,715,653 | € 11,255,856 | ▲ 139% |
| Gross margin | € 1,755,996 | € 1,354,067 | - | - | |
| Profit after taxes | € 753,178 | € 311,857 | € 330,890 | € -141,203 | ▼ € 472,093 |
| Equity | € 3,300,012 | € 1,711,869 | € 2,042,758 | € 1,901,555 | ▼ 7% |
| Total debts | € 1,331,402 | € 2,535,758 | € 1,800,312 | € 5,091,687 | ▲ 183% |
| Cash | € 522,053 | € 321,935 | € 111,772 | € 42,088 | ▼ 62% |
| Land & buildings | € 526,769 | € 489,560 | € 472,083 | € 442,054 | ▼ 6% |
| Retained profit | € 3,287,612 | € 1,699,469 | € 2,030,358 | € 1,889,155 | ▼ 7% |
| Dividend | € 0 | € 1,900,000 | € 0 | € 0 | |
| Bank debt | € 432,972 | € 385,306 | € 986,809 | € 1,218,352 | ▲ 23% |
| Balance sheet total | € 4,631,414 | € 4,247,626 | € 3,843,071 | € 6,993,242 | ▲ 82% |
| Employees (FTE) | 13.9 | 17.5 | 17.1 | 18.4 | ▲ 1.3 |
Key figures of ULTIMEDI, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ULTIMEDI?
What happened at ULTIMEDI in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 141,203 (▼ € 472,093 vs 2024). Source: NBB ↗
- Bobbie Pharmaceutical Services BV became a director. NBB
- Bobbie Company BV stepped down as director. NBB
- Cecile Hoogmartens became a director. NBB
- CéVéGé BV became a director. NBB
- Bobbie Company BV became a director. NBB
- New establishment in Wingene. KBO
- Start of the company according to the CBE. KBO
In short
From € 753,178 profit in 2023 to € 141,203 loss in 2025.
Paid € 483,148 in corporate taxes since 2023.
Best year ever: 2023, with € 753,178 profit.
On average € 77,400 of value added per employee in 2024.
A new publication or filing at ULTIMEDI? We notify you, reason included.
Follow ULTIMEDIDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ULTIMEDI are Bobbie Pharmaceutical Services BV, Cecile Hoogmartens and CéVéGé BV. The shares are held by Bobbie Pharmaceutical Services (100%).
Directors
According to the 2025 annual accounts
Bobbie Pharmaceutical Services BV
Managing director · represented by Benoit Devroe
Also active at: BOFAR, Farmadistri, VERGEL, FARMAZORG, bmedi, MEDIPACK IMMO
since 2025
since 2023
Director · represented by Chris Verstraete
Also active at: BOFAR, Bobbie Pharmaceutical Services, VERGEL, bmedi
since 2023
Managing director · represented by Benoit Devroe
Also active at: BOFAR, Bobbie Pharmaceutical Services, VERGEL, bmedi
since 2023 · until 2025
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Flandria 5
8750 Wingene
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0834.340.946
- VAT number
- BE 0834.340.946
- Registered office
- Flandria 5, 8750 Wingene
- Names & denominations
- ULTIMEDI
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 March 2011
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische en medische artikelen